Eutropics Phamraceuticals

Eutropics Pharmaceuticals is a biotechnology company that has developed a proprietary diagnostic platform known as PRIMABS-Dx. This technology utilizes conformation-specific antibodies to directly measure critical protein-protein interactions within the BCL-2 family, which are responsible for determining a cancer cell's sensitivity to apoptosis-targeted therapies. Unlike traditional genomic profiling, the platform provides functional readouts of mitochondrial priming by assessing how cancer cells respond to therapy ex vivo. The system is designed to integrate into standard clinical laboratory workflows, such as flow cytometry and immunohistochemistry, allowing for the processing of peripheral blood, bone marrow, and fixed solid tumor tissue samples.

This platform serves as a critical tool for precision medicine, helping clinicians and pharmaceutical researchers identify patient-specific treatment strategies for hematologic malignancies, such as acute myeloid leukemia (AML) and multiple myeloma. By identifying priming patterns, the technology assists in predicting therapeutic responses, selecting appropriate drug regimens, and detecting mechanisms of drug resistance, such as the shift in BCL-2 family dependencies that can occur during treatment. Eutropics supports both clinical applications and drug development programs through academic and clinical research collaborations with institutions like MD Anderson Cancer Center, Massachusetts General Brigham, and the Keck School of Medicine of USC.